LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

7.49 -1.58

Overview

Share price change

24h

Current

Min

7.43

Max

7.5

Key metrics

By Trading Economics

Income

5.7M

-30M

Sales

3.1M

34M

Profit margin

-89.424

Employees

182

EBITDA

5.2M

-35M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+206.26% upside

Dividends

By Dow Jones

Next Earnings

29 Oct 2025

Market Stats

By TradingEconomics

Market Cap

55M

738M

Previous open

9.07

Previous close

7.49

News Sentiment

By Acuity

50%

50%

166 / 372 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Aug 2025, 18:43 UTC

Major Market Movers

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29 Aug 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

29 Aug 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

29 Aug 2025, 20:24 UTC

Earnings

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29 Aug 2025, 20:17 UTC

Earnings

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 Aug 2025, 19:18 UTC

Market Talk

Oil Futures End Week With Modest Gains -- Market Talk

29 Aug 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29 Aug 2025, 18:36 UTC

Earnings

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29 Aug 2025, 18:26 UTC

Earnings

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29 Aug 2025, 17:48 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29 Aug 2025, 17:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29 Aug 2025, 16:57 UTC

Earnings

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 Aug 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29 Aug 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29 Aug 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29 Aug 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29 Aug 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29 Aug 2025, 16:24 UTC

Acquisitions, Mergers, Takeovers

BBVA Adjusts Offer for Banco de Sabadell

29 Aug 2025, 16:23 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29 Aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 Aug 2025, 16:06 UTC

Market Talk

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29 Aug 2025, 15:12 UTC

Market Talk
Earnings

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29 Aug 2025, 15:09 UTC

Earnings

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29 Aug 2025, 15:01 UTC

Market Talk

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29 Aug 2025, 14:49 UTC

Earnings

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 Aug 2025, 14:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 Aug 2025, 14:49 UTC

Market Talk

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29 Aug 2025, 14:48 UTC

Earnings

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29 Aug 2025, 14:43 UTC

Market Talk

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

29 Aug 2025, 14:38 UTC

Market Talk

With Canada's Economy Soft, Central Bank Easing Looks Likely -- Market Talk

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

206.26% upside

12 Months Forecast

Average 23 USD  206.26%

High 34 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

166 / 372 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.